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Abstract
Background: Chronic cough, defined it lasts more than 8 weeks. The symptom is common, but highly
troublesome, and it reduces quality of life. Despite much effort to develop a protocol for diagnosis and treatment
of chronic cough, it remains problematic to determine its cause. As a result, treatment is often unsuccessful. Thus,
there is much interest regarding the use of symptomatic drugs to control chronic cough.
Maekmoondong-tang is widely used in East Asian countries to treat chronic dry cough. Several experimental studies
have reported that the herbal medicine has immunomodulatory and antitussive effects. Clinical studies involving
Maekmoondong-tang have also been carried out; however, these studies have involved treating various diseases as
a whole rather than chronic cough itself. Thus, we aim to evaluate the efficacy and safety of Maekmoondong-tang
in chronic dry cough patients with a randomized controlled trial.
Methods/Design: This study is designed as an exploratory, single-center, placebo-controlled, double-blind,
randomized, parallel group clinical trial. Patients with dry cough that has lasted more than 8 weeks will be
recruited, after a 1-week run-in period, and randomly allocated to either the Maekmoondong-tang treatment group
or the placebo group. The patients will receive Maekmoondong-tang or placebo granules 3 times daily for 4 weeks,
with a 2-week follow-up. The primary outcome is a 10-point cough diary that will be recorded on a daily basis. The
secondary outcomes comprise a cough visual analog scale, the Leicester Cough Questionnaire (Korean version), the
Pattern Identification for Chronic Cough Questionnaire, biomarkers, safety testing, etc. Adverse events will also be
reported.
Discussion: This trial will assess the efficacy and safety of Maekmoondong-tang in chronic dry cough.
Trial registration: Korean Clinical Trial Registry (http://cris.nih.go.kr; registration number: KCT0001646). Date of
registration: October 5 2015
Keywords: Chronic dry cough, Maekmoondong-tang, Efficacy, Safety, Herbal medicine
Background
Chronic cough, defined as lasting more than 8 weeks, is a
common respiratory symptom among outpatients [1–3].
It is associated with a substantial deterioration in quality
of life, with various effects on all aspects of health, such as
retching, vomiting, chest pain, rib fracture, incontinence,
fainting, and depression [2, 4]. The management and
treatment of chronic cough is often unsatisfactory, al-
though a few clinical guidelines are available [5]. The most
common conditions that lead to chronic cough are
asthma, upper airway cough syndrome, and gastroesopha-
geal reflux disease with a normal chest radiograph [3].
However, in up to 46 % of patients, no single cause is evi-
dent [6], and the treatment success rate has been reported
to be as low as 58 % [7]. The number of patients with un-
explained cough who do not improve after cause-specific
treatment is increasing; therefore, clinicians and patients
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alike are concerned about cough treatment [5]. Despite
this, studies into the efficacy of antitussive drugs to man-
age chronic cough have yielded inconsistent results. More-
over, the agents used showed adverse effects [8], and
evidence for the efficacy of inhaled corticosteroids (ICS),
which are recommended for chronic cough, is not strong
[9]. Therefore, a limited range of drugs is available to care
chronic cough.
Maekmoondong-tang (MMDT; Mai-men-dong-tang in
Chinese; Bakumondo-to or TJ-29 in Japanese) was intro-
duced in the Geumgweyoryak, a classical textbook of
traditional Chinese medicine [10]. MMDT, which con-
sists of six herbs, is widely used to treat cough caused by
lung yin deficiency, which is a common pattern in
chronic dry cough according to traditional Korean medi-
cine (TKM) [11]. Here, “yin” refers in general to body
fluids, and “lung yin deficiency” denotes a shortage of
yin of the lung; that is, a dry lung. This lung yin defi-
ciency is manifested by unproductive cough, afternoon
fever, night sweating, flushed cheeks, dry throat, red and
dry tongue, etc. [12]. According to the Donguibogam,
which was published in 1613 by the royal physician Heo
Jun and has been a popular piece of TKM literature,
MMDT is also used for heat-induced asthma, which is
caused by the lung or stomach yin deficiency [13]. The
immunomodulatory [14] and anti-asthmatic [15, 16] ef-
fects of MMDT have been investigated in several studies.
A peripheral antitussive effect of MMDT has also been
reported [17, 18]; that is, the drug can be used to treat
coughs that are not controlled by central cough suppres-
sants like codeine. The results of case–control clinical
studies have shown that MMDT reduces cough hyper-
sensitivity [19, 20], which is another recently proposed
cause of chronic cough [21, 22]. MMDT clinical trials
have been carried out, but have focused only on specific
diseases, such as asthma [23], chronic obstructive pul-
monary disease (COPD) [24], and post-infectious cough
[25, 26], not on the symptom itself. To our knowledge,
no clinical trials have studied the efficacy of MMDT on
chronic dry cough with normal chest X-ray.
Therefore, we aim to investigate the efficacy and safety
of MMDT for chronic dry cough. We will evaluate
cough symptoms in terms of their intensity and severity
using a cough diary, cough visual analog scale (VAS),
and cough-specific quality of life questionnaire.
Methods/Design
Objective
The objective of this trial is to assess the efficacy and safety
of MMDT for the adult patients with chronic dry cough.
Hypothesis
We primarily hypothesize that 4 weeks of MMDT inter-
vention eases chronic dry cough in adults more
efficaciously than a placebo control. We will evaluate
this hypothesis using a 10-point cough diary.
Design
This study is an exploratory, single-center, placebo-
controlled, double-blind, randomized, parallel group
clinical trial. Figure 1 shows a flow chart of the study. Eli-
gibility for the study will be decided on the basis of a daily
cough diary, which participants will keep during the 1-
week run-in period. Those with a cough diary symptom
score of more than 2, as well as more than 10 entries in
the cough diary during the run-in period, will be enrolled
pending the inclusion and exclusion criteria below.
Participants
Inclusion, exclusion, and withdrawal criteria
The inclusion criteria are: (1) age between 19 and 75 years;
(2) chronic cough that has lasted more than 8 weeks; (3)
dry cough (sputum frequency of 5 or fewer times per day,
and sputum volume less than 10 ml per day, on the basis
of the Sputum Severity Evaluation Standard of the Korean
Ministry of Food and Drug Safety); (4) provision of written
informed consent.
The exclusion criteria are: (1) abnormal pulmonary
function test (forced vital capacity, or forced expiratory
volume in 1 s, < 80 % of predicted); (2) abnormal chest
X-ray; (3) acute respiratory disease, including upper re-
spiratory tract infection, during the previous 4 weeks; (4)
chronic pulmonary diseases (COPD, idiopathic pulmon-
ary fibrosis, bronchiectasis, etc.) during the previous 2
years; (5) diagnosis of malignant tumor during the previ-
ous 5 years; (6) history of smoking (≥20 packs [400 ciga-
rettes] during the participants’ lifetime); (7) treatment
taking an angiotensin-converting-enzyme inhibitor at
present or during the previous 4 months; (8) current or
the precious 2-week use of antitussive drugs, glucocorti-
coids, leukotriene receptor antagonists, anticholinergic
drugs, long-acting β2 agonists or any herbal medication;
(9) antihistamine treatment during the previous 3 days;
(10) aspartate aminotransferase (AST) or alanine amino-
transferase (ALT) levels at least twofold higher than the
upper normal limit, or a serum creatinine levels at least
1.2-fold the upper normal limit; (11) a mean cough diary
score of less than 2 during the 1-week run-in period;
(12) fewer than 10 entries in the cough diary during the
1-week run-in period; (13) pregnancy or breastfeeding;
(14) illiteracy or cognitive impairment; (15) unsuitability
as judged by the investigators.
The rejection and withdrawal criteria are: (1) treat-
ment that might influence the results of the trial without
the agreement of an investigator; (2) use of forbidden
drugs, such as antitussives, glucocorticoids, leukotriene
receptor antagonists, anticholinergics, and long-acting
β2 agonists; (3) participants not following the protocol,
Kim et al. BMC Complementary and Alternative Medicine  (2016) 16:46 Page 2 of 8
or taking < 80 % of the prescribed doses; (4) a serious ad-
verse event (SAE) during the trial; (5) voluntary with-
drawal from the trial; (6) unsuitability as judged by the
investigators.
Recruitment
Through advertisements and referrals, a total of 58 pa-
tients with chronic dry cough will be recruited at the
Korean Medicine Clinical Trial Center (K-CTC) of the
Kyung Hee University Korean Medicine Hospital.
Ethics
This trial has been authorized by the Institutional Review
Board of the Kyung Hee University Korean Medicine
Hospital (approval number: KOMCIRB-150213-HRBR-
007). The protocol accords with both the Declaration of
Helsinki and Good Clinical Practice (GCP) Guidelines.
Signed informed consent forms will be obtained from all
eligible participants before enrollment.
This trial is registered with the Korean Clinical Trial
Registry (registration number: KCT0001646).
Randomization and Concealment
An independent statistician who is unware of the design
and purpose of the study will generate a randomization
table using R software (version 3.2.0; The R Foundation
for Statistical Computing); specifically, a block size of 4
will be used, and the 58 patients will be randomly
allocated group in a 1:1 ratio either to the MMDT treat-
ment group or to the placebo control. The statistician
will keep the randomization lists and inform the re-
searcher of the matching cord number either by text
message or via mobile communication application.
Blinding
Participants, investigators, and the clinical trial pharma-
cist will be blinded to the treatment allocation through-
out the course of the study. The placebo granules will be
similar to the MMDT granules in appearance, taste, and
scent. The manufacturer will label the random and
product codes on the packaging, and the code labeling
will conform to the GCP guidelines. The clinical trial
pharmacist at the K-CTC will provide the packaged
drugs to the patients on the basis of the randomization
number. The statistician will uncover the blinding when
necessary, such as an SAE occurs. A blinding test will be




The MMDT group will receive MMDT granules (3 g/
pouch, 3 times per day—before each meal—for 4 weeks;
dosage based on the requirements of the Korean Minis-
try of Food and Drug Safety). The MMDT granules are
manufactured as “Maekgeuron Granules” by Hanpoong
Fig. 1 Study flow chart
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Pharm & Food Co. Ltd. (Jeonju, Republic of Korea), a
company that has obtained Korea Good Manufacturing
Practice authorization. Both the MMDT granules and
their ingredients have been approved by the Korean
Ministry of Food and Drug Safety. Three grams (dry
weight) of granules (water-extracted MMDT combined
with starch and lactose) contain six herbs: Ophiopogo-
nis Tuber (Liriope platyphylla Wang et Tang, family
Liliaceae; 3.33 g), Pinelliae Tuber (Pinellia ternata
Breitenbach, family Araceae; 1.67 g), Glycyrrhizae
Radix (Glycyrrhiza uralensis Fischer, family Legumino-
sae; 0.67 g), Zizyphi Fructus (Zizyphus jujuba Miller
var. inermis Rehder, family Rhamnaceae; 1.00 g), Ginseng
Radix (Panax ginseng C. A. Meyer, family Araliaceae;
0.67 g), and Oryzae Semen (Oryza sativa Linné, family
Gramineae; 3.33 g). This 10 g mixture yields 2.07 g of
soft extract after boiling in water. With starch and
lactose added, the final MMDT of 3 g is obtained by
drying under reduced pressure. Each 3 g dose of
MMDT contains 3.1 mg of glycyrrhzin acid and 0.31
mg of gincenoside Rb1 (Rg1). Voucher specimens will
be reserved at the research library of Hanpoong Pharm
& Food Company.
Placebo
The control group will receive placebo granules (3 g/
pouch, 3 times per day—before each meal—for 4 weeks).
The placebo was manufactured by the Jeonnam Bioindus-
try Foundation Food Research Center (JBF), following the
placebo guidelines of the Korean Ministry of Food and
Drug Safety. The granules do not contain any active ingre-
dients, but are similar in appearance, taste, and scent to
the MMDTgranules.
All products were packaged by JBF (Naju, Republic of
Korea). Either Forty-two MMDT or placebo pouches
will be provided to each randomized participant at visit
1 (week 0 ± 3 days) and visit 2 (week 2 ± 3 days). The
products will be stored at the K-CTC clinical research
pharmacy in Kyunghee University Korean Medicine
Hospital, and an independent and trained pharmacist
will manage all procedures associated with the drugs.
The study process is outlined in Table 1.
Concomitant and forbidden drugs
If participants experience unbearable cough at night,
taking one capsule acetylcysteine is permitted; this anti-
tussive will be delivered to the patients along with the
MMDT or placebo granules. If this does not improve
the cough, the participant will visit the K-CTC for exam-
ination and appropriate management. The participants
will be asked to record whether they take the antitussive
agent or not. Other drugs that alleviate cough—such as
other antitussives, glucocorticoids, leukotriene receptor
antagonists, anticholinergics, short-acting β2 agonists,
long-acting β2 agonists, and antihistamines—are prohib-
ited. Drugs which are not related to cough symptoms
will be permitted. The name, duration, and dosage of




The primary outcome is the cough diary score at week
4. The cough diary score on the last day of the 1-week
run-in period will be taken as the baseline score of
participants who will be enrolled and randomized for
the trial.
The cough symptom scoring recommended by Spector
et al. will be used in this study [27]. The daily cough
diary consists of two parts: daytime (08:00–20:00) and
nighttime (20:00–08:00) cough symptoms. Patients will
be required to evaluate their symptoms twice per day
(daytime and nighttime). Daytime cough symptoms will
be graded from zero to five as follows: 0—no cough;
1—cough for one short period; 2—cough for two or
more short periods; 3—frequent coughs that did not
interfere with usual daytime activities; 4—frequent
coughs that did interfere with usual daytime activities;
and 5—distressing coughs for most of the day. Nighttime
cough symptoms will be graded from zero to five as fol-
lows: 0—no cough during the night; 1—cough on waking
only; 2—waking once or early precisely because of
cough; 3—waking frequently due to cough; 4—wakeful-
ness for most of the night due to cough; and 5—distres-
sing coughs preventing sleep. The total cough score
(from 0 to 10) is the sum of the daytime and nighttime
cough symptom scores.
Secondary outcomes
Cough visual analog scale The cough VAS is an overall
rating scale for cough frequency and severity ranging
from 0 (no cough) to 10 (unbearable cough). The scale
will be checked at baseline, and at weeks 2, 4, and 6 (fol-
low-up visit). The cough VAS mean scores will be re-
corded at weeks 2, 4, and 6.
The Leicester Cough Questionnaire (Korean version)
The Leicester Cough Questionnaire (LCQ) is widely
used to measure quality of life in cough patients. It was
developed by Birring [28], and has been validated in
several languages, including Korean (LCQ-K) [29]. The
LCQ comprises three domains: physical, mental, and
social quality of life; a total of 19 items are scored on 7-
point Likert scales. A higher score indicates a more
healthy state. Several studies [2, 30, 31] have demon-
strated a correlation between cough symptom severity
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and LCQ score. At week 4, we will compare the MMDT
and placebo groups in terms of mean LCQ-K scores.
Pattern Identification for Chronic Cough Question-
naire The Pattern Identification for Chronic Cough
Questionnaire (PICCQ) is used to identify patterns in
chronic cough patients. We developed this questionnaire
using the Delphi method [32], and conducted clinical re-
search to confirm its validity and reliability. The PICCQ
consists of four patterns: wind-cold, phlegm-turbidity,
fire-heat, and deficiency (lung deficiency and kidney
yang deficiency). The PICCQ comprises 38 items scored
on 5-point Likert scales. A patient’s pattern is calculated
by summing the scores of each item. We will investigate
the chronic cough pattern distribution in chronic dry
cough patients, as well as the correlation between
chronic cough pattern and the efficacy of MMDT.
Cold-Heat Pattern Questionnaire We will use the vali-
dated Cold-Heat Pattern Questionnaire, which consists
of 20 symptom items (10 items to assess cold pattern
and 10 to assess heat pattern) [33]. Each item requires
only a “yes” or “no” response depending on the patient’s
tendencies during the previous week. The total numbers
of items that a participant responds ‘yes’ will be the cold
or heat pattern score, respectively, for the responder.
We will investigate the Cold-Heat Pattern in chronic dry
cough patients, as well as the correlation between the
cold-heat pattern scores and the efficacy of MMDT.
Table 1 Study process: treatment and outcome measurements
Activity Screening Visit 1 Visit 2 Visit 3 Follow up
Time schedule -Week 1 Baseline Week 2 Week 4 Week 6
Window visit ±3 days ±3 days ±3 days ±3 days
Informed consent X
Demographics X




Safety test X X X
Chest X-ray X
Pulmonary function test X
Safety test X
Methacholine bronchial challenge testa X
Nasal endoscopya X
Distribute cough diary card X X X X
Randomization X
Height/weight/body mass index X
Vital sign X
Cough diary score X X X X
Cough visual analogue score X X X X
Leicester cough ques-tionnaire Korean versi- on X X X
Pattern identification for chronic cough question-naire X X
Cold-Heat pattern questionnaire X X
Yin deficiency scale X X
Hematological biomarker X X
Immunologic biomarkers X X
Investigational Produce X X
Compliance X X
Adverse events investi-gation X X
Concomitant therapy eva- luation X X X X
aThe test will be performed as needed, according to the judgment of the investigator
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Yin Deficiency Scale We will use the validated yin defi-
ciency scale developed by Park [34]. This questionnaire
consists of 27 items, each of which uses a 7-point Likert
scale; the cut-off point was defined as 10 points. We will
use the yin deficiency scale to evaluate chronic dry
cough patients, as well as to investigate the correlation
between the yin deficiency pattern and the efficacy of
MMDT.
Biomarkers
Biomarkers that reflect chronic cough and airway in-
flammation [35] will be evaluated. These include blood
neutrophils, eosinophil counts, serum immunoglobulin
E levels, sputum eosinophilic cationic protein levels, and
proinflammatory cytokines such as tumor necrosis factor
alpha, interleukin (IL)-4, IL-5, IL-8, IL-10, and IL-13.
Adverse event reporting
An adverse event (AE) is an undesirable, unintended
sign, symptom, or disease that does not necessarily have
a cause-and-effect relationship with the intervention
evaluated in a clinical trial. We will carry out continuous
monitoring of AEs and make any decision in this regard
on the basis of both objective and subjective signs, as
well as blood test results. Appropriate measures will be
taken immediately to minimize any SAEs.
Safety outcomes
Safety will be investigated using adverse reaction reports
and clinical laboratory tests; namely, liver function tests
(AST, ALT, alkaline phosphatase [ALP], total bilirubin
[TB], and γ-glutamyltranspeptidase [GGT] levels), renal
function tests (blood urea nitrogen [BUN] and creatinine
levels), and serum sodium and potassium levels. All
women of childbearing age will also undergo human
chorionic gonadotropin testing.
Sample size calculation
We referred a randomized controlled trial (RCT) that
was conducted to demonstrate the clinical efficacy of a
herbal medication for the patients with cough variant
asthma (CVA) [36]. It was inevitable because no RCTs
have been carried out that address the comprehensive
chronic cough symptom using a herbal mediation.
Furthermore, the main manifestation of CVA is cough
lasting more than 8 weeks without any abnormal pul-
monary functions; this is very similar to clinical charac-
teristics of the eligible participants recruited in this
study.
Using a cough diary score, the CVA study compared
the efficacy of a herbal medicine with that of standard
therapy (leukotriene receptor antagonist combined with
methylxanthine) for 2 weeks. The calculated effect size
was 0.699 (α = 0.05, 1-β = 0.8, 2-tailed test). Because of
the discrepancy in comparators and study duration be-
tween the previous and planned studies, we determined
to eliminate the effect of standard therapy and add the
effect of longer treatment duration; this resulted in an
adjusted effect size of 0.85. Assuming a 20 % dropout
rate, and an allocation ratio of 1, we have calculated the
necessary sample size to be 58 participants (29 in each
group). The above calculations were performed using
G*Power™ software (ver. 3.1.9.2) for Mac.
Statistical analysis plan
Data entry and management will be completed by an in-
dependent data administrator to ensure data accuracy.
We will analyze the efficacy and safety of MMDT using
the “intent-to-treat” (ITT) principle. Subordinately, we
will also present the results of the analysis based on the
“per protocol” principle.
Patient groups for data analysis
Intent-to-treat population The ITT population will in-
clude all participants treated with at least one dose of
the study drug and who keep and return a daily cough
diary for at least one day of recordings.
Per-protocol population The per-protocol population
will include patients who take more than 80 % of the
prescribed doses of the study drug, fill in the daily cough
diary on 80 % of the study days, and return their diary
to the researchers.
MMDT responder/non-responder groups An MMDT
treatment responder is defined as a participant who ex-
hibits a 75 % decrease in cough diary score after 4 weeks
of treatment; all other participants in the MMDT treat-
ment group will be included in the non-responder
group. We will analyze the correlations between MMDT
responder group and all TKM patterns.
Statistical analysis
Descriptive statistics will be used for continuous
variables, and frequencies for categorical variables. The
“last observation carried forward” (LOCF) principle will
be used to compensate for missing data. The LOCF
principle involves replacement of missing data with the
last observed value to obtain a complete database.
When the assumption of normality is satisfied will a t-
test be used to compare the two groups in terms of the
primary outcome (mean cough diary score at week 4).
Otherwise, the Mann–Whitney U-test will be used.
Other continuous variables, such as mean efficacy mea-
surements (cough VAS score or LCQ scores), safety tests
(AST, ALT, ALP, TB, GGT, BUN, creatinine, sodium or
potassium levels), and biomarkers will be analyzed using
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the same statistical methods. Associations between the
MMDT responders and non-responders with regard to
each identified pattern will be estimated using a logistic
regression model, which will be adjusted for covariates.
All data will be analyzed using SPSS™ for Windows soft-
ware. The level of significance will be set at a two-sided
P value of 0.05.
We, along with a professional statistician, will perform
the data analysis for the results.
Discussion
Chronic cough is a common symptom in respiratory
outpatients, and in an increasing number, the symptom
is not eased by conventional treatments. Recent studies
have found that substantially fewer patients now respond
fully to treatment [7, 37, 38]. Due to the increased pa-
tients and limited treatment options, chronic cough is
considered a challenging clinical problem.
MMDT is a traditional herbal medicine that has long
been used to treat chronic dry cough; however, the evi-
dence regarding the medicine’s efficacy is sparse. We
aim to demonstrate the efficacy and safety of MMDT in
chronic dry cough via a randomized, placebo-controlled
clinical trial that has been designed in accordance with
the Consolidated Standards of Reporting Trials guide-
lines [39]. In addition, we will investigate the relation-
ship between the specifically identified pattern of cough
and the effectiveness of MMDT. This trial will provide
high-quality evidence on the efficacy and safety of
MMDT in the treatment of chronic dry cough. A larger-
scale clinical trial to evaluate the effectiveness and safety
of MMDT in treating chronic dry cough, based on this
study and with specific cough patterns identified, will be
possible in future.
Trial status
This clinical trial was reviewed by the Ethics Committee
of Kyung Hee University Korean Medicine Hospital in
March 2015. The trial started in September 2015 and is
recruiting patients.
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